 Intensive combination chemotherapy autologous bone marrow transplantation reappearance Philadelphia chromosome-negative cells chronic myelogenous leukemia Fifteen patients Philadelphia chromosome Ph chronic myelogenous leukemia CML ineligible allogeneic bone marrow transplantation BMT alpha-interferon therapy study patients first late chronic phase second chronic phase accelerated phase blastic phase Autologous bone marrow cells median cells/kg median months diagnosis Patients cyclophosphamide days carmustine BCNU days CBV reinfusion autologous bone marrow Hematopoietic recovery rapid toxicity mild patients patient cytomegalovirus pneumonitis Eight patients Ph suppression Ph-positive metaphases autologous BMT Major cytogenetic responses Ph suppression Ph-positive metaphases patients Cytogenetic responses patients Ph-positive marrows patients Ph-mosaic marrows mixture diploid Ph-positive cells results autologous BMT chronic phase advanced phases major cytogenetic responses months whereas cytogenetic responses short time months patients chronic phase previous resistance alpha-interferon therapy sensitive alpha-interferon therapy autologous BMT authors intensive chemotherapy autologous BMT cytogenetic remissions patients Ph-positive CML disease sensitivity alpha-interferon therapy patients useful treatment chronic phase stem cells time previous cytogenetic remission